Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Tax Provisions (2021 - 2025)

Aytu Biopharma (AYTU) has disclosed Tax Provisions for 6 consecutive years, with -$215000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Tax Provisions fell 136.69% to -$215000.0 in Q2 2025 year-over-year; TTM through Dec 2025 was -$320000.0, a 126.87% decrease, with the full-year FY2025 number at -$215000.0, down 111.4% from a year prior.
  • Tax Provisions was -$215000.0 for Q2 2025 at Aytu Biopharma, down from -$105000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $800000.0 in Q4 2023 to a low of -$300000.0 in Q4 2024.
  • A 5-year average of $152454.5 and a median of -$3000.0 in 2021 define the central range for Tax Provisions.
  • Biggest YoY gain for Tax Provisions was 365.08% in 2024; the steepest drop was 137.5% in 2024.
  • Aytu Biopharma's Tax Provisions stood at -$3000.0 in 2021, then crashed by 233.33% to -$10000.0 in 2022, then skyrocketed by 8100.0% to $800000.0 in 2023, then plummeted by 137.5% to -$300000.0 in 2024, then increased by 28.33% to -$215000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Tax Provisions are -$215000.0 (Q2 2025), -$105000.0 (Q1 2025), and -$300000.0 (Q4 2024).